Sepracor, Inc.
84 Waterford Drive
Marlborough,
MA 01752
United States - Map
Phone: 508-481-6700
Fax: 508-357-7499
Web Site: http://www.sepracor.com
| Sepracor Inc., a research-based pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products. The companys marketed products primarily include LUNESTA (eszopiclone), a non-benzodiazepine sedative hypnotic for the treatment of insomnia in adults; XOPENEX (levalbuterol HCl) Inhalation Solution, a short-acting bronchodilator for the treatment or prevention of bronchospasm in patients six years of age and older with reversible obstructive airway disease; XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI) for the treatment or prevention of bronchospasm in adults, adolescents, and children four years of age and older with reversible obstructive airway disease; and BROVANA (arformoterol tartrate) Inhalation Solution, a maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. It also markets OMNARIS (ciclesonide) Nasal Spray, an intranasal formulation of ciclesonide for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children six years of age and older, and with perennial allergic rhinitis in adults and adolescents 12 years of age and older; and ALVESCO (ciclesonide) HFA Inhalation Aerosol, an inhaled corticosteroid in an HFA MDI formulation for the maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. Sepracor markets its products to primary care physicians, allergists, pulmonologists, pediatricians, hospitals, psychiatrists, and sleep specialists in the United States. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Adrian Adams , 58
Chief Exec. Officer, Pres and Exec. Director |
$
1.73M | N/A | Mr. Robert F. Scumaci , 49
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Treasurer |
$
715.00K |
$
15.39M | Dr. Mark H.N. Corrigan M.D., 51
Exec. VP of R&D |
$
763.00K |
$
5.01M | Mr. Andrew I. Koven , 51
Exec. VP, Sec. and Gen. Counsel |
$
761.00K | N/A | Mr. Mark Iwicki , 42
Chief Commercial Officer and Exec. VP |
$
800.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.45% Nasdaq 
0.20%
Profile
